Evidence map›Paper›PMID 38199795›Full record

ArticleAnnals of the rheumatic diseases2024

Immunomodulators and risk for breakthrough COVID-19 after third SARS-CoV-2 mRNA vaccine among patients with rheumatoid arthritis: a cohort study.

Abigail E Schiff, Xiaosong Wang, Naomi J Patel, Yumeko Kawano, Jennifer L Hanberg, Emily N Kowalski, Claire E Cook, Kathleen Mm Vanni, Grace Qian, Katarina J Bade and 6 more

Open access · greenAbstract readLetter
In one paragraph

Article in Annals of the rheumatic diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Abigail E SchiffDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Xiaosong WangDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Naomi J PatelHarvard Medical School, Boston, Massachusetts, USA.
Yumeko KawanoDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID http://orcid.org/0000-0003-2423-5982
Jennifer L HanbergDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Emily N KowalskiDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Claire E CookDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Kathleen Mm VanniDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Grace QianDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Katarina J BadeDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Alene A SaavedraDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Shruthi SrivatsanDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Zachary K WilliamsDivision of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Rathnam K VenkatTufts Medical Center, Boston, Massachusetts, USA.
Zachary S Wallace *Harvard Medical School, Boston, Massachusetts, USA.
Jeffrey A Sparks *Harvard Medical School, Boston, Massachusetts, USA jsparks@bwh.harvard.edu.ORCID http://orcid.org/0000-0002-5556-4618
Brigham and Women's Hospital · USMassachusetts General Hospital · USHarvard University · USTufts Medical Center · US

Funding

VERITY: Value and Evidence in Rheumatology using bioInformaTics, and advanced analYticsP30AR072577 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Daniel Hal Solomon · 2017 to 2026
$9.8M
Joint Biology Consortium Resource-based CenterP30AR070253 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Peter A Nigrovic, Jeffrey Andrew Sparks · 2016 to 2026
$9.4M
Rheumatoid Arthritis-Related Autoantibodies, Articular Inflammation, and RA-Associated Interstitial Lung DiseaseR01AR077607 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI SPARKS, JEFFREY ANDREW · 2021 to 2025
$3.7M
Immunologic and Clinical Sequelae after COVID-19 in Patients with Systemic Autoimmune Rheumatic DiseasesR01AR080659 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI Jeffrey Andrew Sparks · 2023 to 2026
$2.9M
Impact of ANCA Type and Rituximab vs. Cyclophosphamide on Cardiovascular Risk, Mortality, and Quality-Adjusted Life Years inANCA-Associated VasculitisK23AR073334 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI WALLACE, ZACHARY SCOTT · 2018 to 2022
$948k
Personalizing AAV Management by Leveraging Big Data: Targeting Complication ClustersR03AR078938 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI WALLACE, ZACHARY SCOTT · 2021 to 2022
$189k
NIAMS NIH HHS K23 AR073334NIAMS NIH HHS P30 AR070253NIAMS NIH HHS P30 AR072577NIAMS NIH HHS R01 AR077607NIAMS NIH HHS R01 AR080659NIAMS NIH HHS R03 AR078938
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Arthritis, RheumatoidCOVID-19Antibodies, ViralCohort StudiesCOVID-19 VaccinesHumansImmunologic FactorsmRNA VaccinesSARS-CoV-2VaccinationAntibodies, ViralCOVID-19 VaccinesImmunologic FactorsmRNA VaccinesArthritis, RheumatoidCovid-19EpidemiologyRituximabVaccination

Identifiers

PMID38199795
PMCPMC11009046
OpenAlexW4390693783

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.